Xenon Pharmaceuticals Stock Drops After Halting Enrollment in Depression Trials
Xenon Pharmaceuticals (XENE) experienced a significant stock price decline of 31% after announcing the pause of enrollment for its Phase 3 trials targeting major depressive disorder and bipolar disorder. The company cited higher-than-expected neuropsychiatric side effects, including confusion, somnolence, ataxia, and rare cases of psychosis. Xenon plans to adjust dosing strategies before resuming patient recruitment but will wait until Q1 2027 results from the X-NOVA2 trial for major depressive disorder are available. Analysts have responded with mixed reactions: Needham cut its price target while maintaining a Buy rating, Deutsche Bank downgraded Xenon's stock to Hold and lowered its price target significantly, whereas H.C. Wainwright kept its positive outlook. The market is now assessing the impact on Xenon’s growth potential as AZK was central to both epilepsy and psychiatry programs. The company remains cash-positive but trades above estimated fair value. Until trial results are released in early 2027, investor sentiment will likely remain sensitive to updates regarding safety or efficacy.
Tickers: $XENE
Topics: clinical trial pause drug development neuropsychiatric side effects stock decline